Literature DB >> 15650238

HMGA molecules in neuroblastic tumors.

F Cerignoli1, C Ambrosi, M Mellone, I Assimi, Lucia di Marcotullio, A Gulino, G Giannini.   

Abstract

The high mobility group A (HMGA) proteins are thought to work as ancillary transcription factors and to regulate the expression of a growing number of genes through direct binding to DNA or via protein-protein interactions. Both HMGA1 and HMGA2 are important regulators of basic biological processes, including cell growth, differentiation and transformation. Their qualitatively or quantitatively altered expression has been described in a number of human tumors. We studied and review here their expression in neuroblastic tumors. HMGA2 is expressed only in a subset of ex vivo neuroblastoma (NB) tumors and in the embryonic adrenal gland, but it is undetectable in the adult adrenal gland, suggesting that its anomalous expression might be associated with NB tumorigenesis and/or tumor progression. In vitro, its expression is easily detectable in retinoic acid (RA)-resistant cell lines. The exogenous expression of HMGA2 is sufficient to convert RA-sensitive SY5Y NB cells into RA-resistant cells, thus suggesting that HMGA2 might be a relevant player in determining NB cell responses to endogenous or therapeutically important growth inhibitory substances. In contrast, HMGA1 expression is readily detectable in all NB cell lines and tumors, but its expression is consistently higher in less differentiated NBs compared with ganglioneuromas and ganglioneuroblastomas. Interestingly, RA increases HMGA1 expression in RA-resistant NB cells but inhibits it in cells undergoing RA-induced growth inhibition and neuronal differentiation. Our studies indicate that HMGA molecules might be biologically and pathologically relevant factors in neuroblastic tumor development and progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15650238     DOI: 10.1196/annals.1322.013

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  10 in total

Review 1.  The high mobility group A1 molecular switch: turning on cancer - can we turn it off?

Authors:  Tait H Huso; Linda M S Resar
Journal:  Expert Opin Ther Targets       Date:  2014-03-31       Impact factor: 6.902

Review 2.  The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Authors:  T F Sumter; L Xian; T Huso; M Koo; Y-T Chang; T N Almasri; L Chia; C Inglis; D Reid; L M S Resar
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

3.  Enhancement of ATRA-induced differentiation of neuroblastoma cells with LOX/COX inhibitors: an expression profiling study.

Authors:  Petr Chlapek; Martina Redova; Karel Zitterbart; Marketa Hermanova; Jaroslav Sterba; Renata Veselska
Journal:  J Exp Clin Cancer Res       Date:  2010-05-11

4.  Cis-regulation of microRNA expression by scaffold/matrix-attachment regions.

Authors:  Pavithra Lakshminarasimhan Chavali; Keiko Funa; Sreenivas Chavali
Journal:  Nucleic Acids Res       Date:  2011-05-17       Impact factor: 16.971

Review 5.  RNA-Mediated Regulation of HMGA1 Function.

Authors:  Arndt G Benecke; Sebastian Eilebrecht
Journal:  Biomolecules       Date:  2015

6.  Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers.

Authors:  Viera Dobrotkova; Petr Chlapek; Marta Jezova; Katerina Adamkova; Pavel Mazanek; Jaroslav Sterba; Renata Veselska
Journal:  PLoS One       Date:  2019-06-12       Impact factor: 3.240

7.  Comparative Analysis of Putative Prognostic and Predictive Markers in Neuroblastomas: High Expression of PBX1 Is Associated With a Poor Response to Induction Therapy.

Authors:  Renata Veselska; Marta Jezova; Michal Kyr; Pavel Mazanek; Petr Chlapek; Viera Dobrotkova; Jaroslav Sterba
Journal:  Front Oncol       Date:  2019-11-15       Impact factor: 6.244

8.  Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.

Authors:  Veronica Veschi; Marialaura Petroni; Beatrice Cardinali; Carlo Dominici; Isabella Screpanti; Luigi Frati; Armando Bartolazzi; Alberto Gulino; Giuseppe Giannini
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240

Review 9.  microRNAs: a new emerging class of players for disease diagnostics and gene therapy.

Authors:  Baohong Zhang; M A Farwell
Journal:  J Cell Mol Med       Date:  2007-12-14       Impact factor: 5.310

Review 10.  Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy.

Authors:  Viera Dobrotkova; Petr Chlapek; Pavel Mazanek; Jaroslav Sterba; Renata Veselska
Journal:  BMC Cancer       Date:  2018-11-01       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.